‘Paradoxical’ FDA Recalls Report Credits Industry Collaboration For Improved Quality, But Uncovers Troubling Data About Older Devices
This article was originally published in The Silver Sheet
Executive Summary
Medical devices on the market for more than five years are recalled more often than younger ones, according to a recent FDA 10-year retrospective report on corrections and removals. “There is an intuitive appeal to the argument that devices that come to the market in an early point in their lifespan – say, the first year – are more likely to be subject to recalls, but that is simply not true,” CDRH Office of Compliance Director Steven Silverman says. Other notable report findings: troubles with components and software are the leading causes for most recalls; problems with AEDs, ventilators and infusion pumps have triggered an increase in high-risk class I recalls; and domestic manufacturers recall products at a much greater volume than those outside the United States.
You may also be interested in...
2014 Hot Spots: Top 4 Device Quality & Regulatory Topics
Big changes are afoot for inspections, and device stakeholders kept a sharp eye on those issues in 2014, according to readership data from "The Silver Sheet." From a CDRH/ORA plan to create a specialized unit of device-focused field investigators, to IMDRF's mostly untested internationally harmonized single-audit approach, readers (and podcast listeners) couldn't get enough news and tips about inspection activities. A recap of in-depth "Silver Sheet" coverage from the year, including updated expert commentary, follows.
2014 Hot Spots: Top 4 Device Quality & Regulatory Topics
Big changes are afoot for inspections, and device stakeholders kept a sharp eye on those issues in 2014, according to "Silver Sheet" readership data. From a CDRH/ORA plan to create a specialized unit of device-focused field investigators, to IMDRF's mostly untested internationally harmonized single-audit approach, readers (and podcast listeners) couldn't get enough news and tips about inspection activities. Further, FDA is "looking at whether information presented on FDA-483s can be organized in a way that better reflects what we consider to be highest priority quality system deviations that require the most significant attention,” CDRH compliance chief Steven Silverman said. Rounding out the top industry issues last year were device recalls, Unique Device Identification, warning letters and CAPA. A recap of in-depth "Silver Sheet" coverage from the year, including updated expert commentary, follows.
Editors' Picks: Six Themes From 2014
Industry closely scrutinized FDA's premarket review performance as the agency took steps to streamline reviews and remake the U.S. postmarket surveillance system. Meanwhile: device mega-mergers accelerated; one of the most hotly anticipated medtech innovations faltered; and national elections swept in Republican control of Congress. Here is a look back at coverage and analysis from "The Gray Sheet" on six key themes for the medical device and diagnostics industry in 2014.